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RadiotherapyBackground and purpose: Carbonic anhydrase IX (CAIX) plays an important role in pH regulation pro-
cesses critical for tumor cell growth and metastasis. We hypothesize that a dual targeting bioreductive
nitroimidazole based anti-CAIX sulfamide drug (DH348) will reduce tumor growth and sensitize tumors
to irradiation in a CAIX dependent manner.
Material and methods: The effect of the dual targeting anti-CAIX (DH348) and its single targeting control
drugs on extracellular acidiﬁcation and radiosensitivity was examined in HT-29 colorectal carcinoma
cells. Tumor growth and time to reach 4 start volume (T4SV) was monitored for animals receiving
DH348 (10 mg/kg) combined with tumor single dose irradiation (10 Gy).
Results: In vitro, DH348 reduced hypoxia-induced extracellular acidosis, but did not change hypoxic
radiosensitivity. In vivo, DH348 monotherapy decreased tumor growth rate and sensitized tumors to
radiation (enhancement ratio 1.50) without systemic toxicity only for CAIX expressing tumors.
Conclusions: A newly designed nitroimidazole and sulfamide dual targeting drug reduces hypoxic extra-
cellular acidiﬁcation, slows down tumor growth at nontoxic doses and sensitizes tumors to irradiation all
in a CAIX dependent manner, suggesting no ‘‘off-target’’ effects. Our data therefore indicate the potential
utility of a dual drug approach as a new strategy for tumor-speciﬁc targeting.
 2013 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy
and Oncology 108 (2013) 523–528
Open access under CC BY-NC-SA license.Elevated carbonic anhydrase (CA) IX expression has been asso-
ciated with poor prognosis, tumor progression and aggressiveness
[1]. The plasma membrane associated dimeric glycoprotein cata-
lyzes the reversible hydration of carbon dioxide to bicarbonate
and a proton. CAIX is therefore an important component of the
pH regulation systems, which are activated upon anaerobic glycol-
ysis [2]. Its main function during hypoxia is to preserve a neutral
intracellular pH favorable for tumor growth and survival, while
contributing to an acidic extracellular tumor microenvironmentfavorable for invasiveness [3,4]. Since CAIX is implicated in both
extra – and intracellular pH regulation, it has been proposed as a
potential therapeutic target.
A possible approach to target CAIX would be via inhibiting its
enzymatic activity with speciﬁc pharmacological inhibitors [2,5].
Previously, we have demonstrated that inhibitors of CAIX activity
require both protein expression and activation and this is depen-
dent on the tumor oxygenation status [6–8]. Tumor-speciﬁc accu-
mulation was found after administration of ﬂuorescent
sulfonamides at low dosage, while inhibition of tumor growth
was observed at higher dose levels [7,9–11]. Treatment of mam-
mary tumor-bearing mice with novel CAIX-speciﬁc (ureido)-sul-
fonamide and glycosylcoumarin inhibitors resulted in a
signiﬁcant inhibition of primary tumor growth and lung metastasis
formation [11]. Recently, an underexplored class of sulfamate
inhibitors proved to be excellent candidates for low dosage anti-
metastatic drugs in breast cancer therapy [12]. These reports
emphasize that speciﬁc inhibitors of CAIX activity are promising
524 CAIX dual targeting enhances effect IRto pursue for their tumor-speciﬁc therapeutic properties in combi-
nation with conventional therapies. Recently, the CAIX dependent
sensitizing effect of indanesulfonamides [8] and acetazolamide
[13] on respectively radio- and chemotherapy has been
demonstrated.
A different approach to sensitize tumors to irradiation is the use
of the 2-nitroimidazole based hypoxic radiosensitizer misonidaz-
ole. This has shown to improve the radiation response both when
administered in a single or fractionated radiation scheme, however
with high clinical toxicity [14]. The less toxic 5-nitroimidazole
derivative, nimorazole, has shown to reach similar enhancement
ratios as misonidazole in fractionated schedules [14] and resulted
in a highly signiﬁcant beneﬁt in terms of loco-regional tumor con-
trol and disease-free survival [15]. More speciﬁc targeting towards
the hypoxic tumor regions using lower doses is therefore an impor-
tant requisite for new compounds.
The aim of this study was to evaluate the antitumor activity of a
newly designed class of dual targeting nitroimidazole based sulf-
amide drugs with high afﬁnity for CAIX. We hypothesize that these
compounds speciﬁcally block CAIX activity, reduce tumor growth
and sensitize tumors to irradiation in a CAIX dependent manner.Material and methods
Cell culture and model
Exponentially growing colorectal (HT-29, ATCC HTB-38) carci-
noma cells were cultured in Dulbecco’s modiﬁed Eagle’s medium
supplemented with 10% fetal bovine serum. HT-29 colorectal carci-
noma cells harboring a shCAIX (KD) or control shRNA (EV) con-
struct (kindly provided by Adrian Harris, Weatherall Institute of
Molecular Medicine, University of Oxford, John Radcliffe hospital,
Oxford, UK) were engineered as previously described [8]. Low oxy-
gen conditions were acquired in a hypoxic workstation (Ruskinn
INVIVO2 1000). The atmosphere in the chamber consisted of 0.2%
O2 (hypoxia) or <0.02% O2 (anoxia, 0%), 5% CO2 and residual N2.
In parallel, normoxic (20% O2) dishes were incubated in air with
5% CO2. pH of the culture medium was immediately measured at
the end of each experiment as previously described [6].Inhibition CAIX activity
The structure and Ki value of the different compounds are de-
picted in Fig. 1A. Compounds were dissolved in culture medium
containing 0.5% DMSO at the indicated ﬁnal concentrations just be-
fore addition to the cells. For the animal experiments, DH348 was
dissolved in NaCl 0.9% containing 1% DMSO to a ﬁnal concentration
of 10 mg/kg and injected intravenously via a lateral tail vein.Immunoblotting
Experiments were performed as previously described [6]. Anti-
bodies used were M75 (kindly provided by Silvia Pastorekova,
Institute of Virology, Slovak Academy of Science, Bratislava, Slovak
Republic) against CAIX or b-actin (Cell Signaling) as loading
control.Clonogenic survival
Cells were exposed to normoxia or anoxia for 24 h, subse-
quently irradiated (225 kV Philips X-ray tube), trypsinized and pla-
ted in triplicate for clonogenic survival. Cells were allowed to form
colonies during 10 days, which were ﬁxed and stained with 0.4%
methylene blue in 70% ethanol. Afterwards, colonies were counted
in an automated way (Oxford Optronix).Animal experiments
All experiments were in accordance with local institutional
guidelines for animal welfare and were approved by the Animal
Ethics Committee of the University. 1.5e6 cells were resuspended
in Basement Membrane Matrix (Matrigel™ BD Biosciences) and in-
jected subcutaneously into the lateral ﬂank of adult NMRI-nu mice
(28–32 g). Intravenous DH348 treatment started at a tumor vol-
ume of 193 ± 66 mm3 for 5 days (10 mg/kg daily) and irradiation
(10 Gy single dose [8]) was performed at day 3. Tumor growth
was monitored until reaching 4 the volume at irradiation time
(T4SV) and treatment toxicity was scored by body weight mea-
surements. Radiation sensitization enhancement ratios (SER) are
calculated as the ratios of the mean T4SV of the DH348 compared
to the vehicle treated irradiation groups.Immunohistochemistry
Frozen sections were ﬁxed in 4% formalin and incubated with
normal goat serum. Contiguous sections were stained using rabbit
anti-pimonidazole (1:250, NPI Inc.) or rabbit anti-CAIX (1:1000,
Novus Biologicals). Secondary incubation was done with biotinyla-
ted goat anti-rabbit antibody (1:200 and 1:400 for CAIX and
pimonidazole, respectively, DAKO). Detection was done with Vec-
tastain ABC kit (Vector Laboratories) followed by 0.033% hydrogen
peroxide in 10% diaminobenzidine (DAB; Sigma–Aldrich). Staining
without primary antibody served as negative control. The sections
were viewed (magniﬁcation 4x) by means of a Nikon Eclipse E800
microscope (Nikon Instruments Inc.).Statistics
All statistical analyses were performed with GraphPad Prism
version 5.03 for Windows (GraphPad Software, 2009, California,
USA). A non-parametric Mann–Whitney U test for small groups
was used to determine the statistical signiﬁcance of differences be-
tween two independent groups of variables. For all tests, a P < 0.05
was considered signiﬁcant.Results
HT-29 colorectal carcinoma cells showed elevated CAIX protein
levels in response to anoxia (Fig. 1B) and its expression is hetero-
geneous across tumors, overlapping the pimonidazole-positive
hypoxic areas (Fig. 1C). To examine the necessity for CAIX activity
for extracellular acidiﬁcation under hypoxic conditions, the effect
of the dual targeting compound DH348 on hypoxia-induced
changes in extracellular pH was tested. A signiﬁcant dose-depen-
dent (P < 0.05) reduction in hypoxia-induced extracellular acidosis
was observed, while the effect on cells exposed to ambient air was
negligible (Fig. 1D). To explore the effect of CAIX activity inhibition
on tumor growth and radiotherapy response, HT-29 tumor bearing
mice were treated with DH348 and subsequently irradiated. Tumor
growth was signiﬁcantly (P < 0.01) inhibited in DH348-treated
mice versus mice receiving vehicle only. The time to reach 4 irra-
diation starting volume (T4SV) was increased (P < 0.001) when
treated with single dose irradiation, which was further enhanced
(P < 0.05) upon combination with DH348 (Fig. 1E) resulting in a
radiation sensitization enhancement ratio (SER) of 1.50.
To establish a causal relationship between CAIX expression and
its therapeutic effect in more detail, CA9was genetically silenced in
a constitutive manner. A clear reduction in CAIX protein levels was
observed for the CAIX knock-down (KD) cell line as compared with
a control shRNA (EV) cell line (Fig. 2A). HT-29 EV xenografts
demonstrated a robust and heterogeneous CAIX expression, which
co-localized with the hypoxia marker pimonidazole. CAIX levels
Fig. 1. (A) Chemical structure and afﬁnity (Ki) for CAI, CAII and CAIX of the dual targeting compound DH348 and its respective single targeting controls. (B) Western blot
analysis of CAIX expression in HT-29 cells under normoxic (20%) and anoxic (0%) conditions. b-Actin was used as loading control. (C) Representative pimonidazole (PIMO) and
CAIX immunohistochemical staining of HT-29 tumors resected 5 days after inhibitor treatment. Negative control indicates staining without the primary antibody. Bar
indicates 1 mm length. (D) Extracellular acidiﬁcation of cells exposed to normoxia (20%) and hypoxia (0.2%) upon treatment with 0.1 or 1.0 mM DH348. Data show the
mean ± SD of at least three independent experiments and are expressed as the difference between pHe values (DpHe = pHafter incubation  pHbefore incubation). (E) DH348 (10 mg/
kg, 5 days) was administered intravenously when tumors reached an average size of 200 mm3 and tumors were irradiated (10 Gy) at day 3 (set to 0) of this treatment. Tumor
growth was monitored until reaching 4 the volume at irradiation time (T4SV). Data represent the mean ± SD of six to nine independent animals. Asterisks indicate
statistical signiﬁcance (⁄P < 0.05; ⁄⁄P < 0.01).
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affecting the presence of hypoxia as assessed with pimonidazole
(Fig. 2B). Next we examined whether CAIX depletion in vitro re-
sulted in a decreased extracellular acidiﬁcation upon hypoxia.
Extracellular acidosis upon hypoxia was signiﬁcantly reduced
(30%, P < 0.01) upon CAIX depletion (Fig. 2C). Furthermore, we
investigated if pharmacological inhibition of CAIX activity wouldmimic the effect of CAIX silencing. Besides the dual targeting drug
DH348, the single targeting controls (NKP46 = 5-nitroimidazole: 5-
NI and NKP64 = sulfamide: Sulf) were evaluated for their capacity
to reduce the CAIX dependent extracellular acidiﬁcation. Both
DH348 and Sulf reduced the hypoxic extracellular acidosis (43%
and 29% for 1.0 and 0.1 mM, respectively, P < 0.05) to similar levels
as seen for the KD cells. No effect was seen when cells were
Fig. 2. (A) Western blot analysis of CAIX expression in HT-29 CAIX expressing (EV) and CAIX silenced (KD) cells under normoxic (20%) and anoxic (0%) conditions. (B)
Representative pimonidazole (PIMO) and CAIX immunohistochemical staining of EV and KD tumors resected 5 days after inhibitor treatment. (C) Extracellular acidiﬁcation of
EV and KD cells exposed to normoxia (20%) and hypoxia (0.2%) upon treatment with 0.1 or 1.0 mM DH348 or controls. Data represent the mean ± SD of at least three
independent experiments. (D) Clonogenic survival assay after exposure to different doses of irradiation upon normoxia (20%: 0, 2, 4, 6 and 8 Gy) and anoxia (0%: 0, 4, 8, 12 and
16 Gy) exposed EV and KD cells after pre-treatment (24 h) with 33 lM DH348 or controls. Data show mean ± SD of at least three independent experiments. Asterisks indicate
statistical signiﬁcance compared to EV treated with vehicle under hypoxia (⁄P < 0.05; ⁄⁄P < 0.01).
526 CAIX dual targeting enhances effect IRincubated in ambient air or upon addition to KD cells. Similarly, 5-
NI did not affect extracellular acidosis under any experimental
conditions (Fig. 2C). To examine if inhibition of CAIX activity inﬂu-
ences radiosensitivity, the in vitro response of EV and KD cells to
varying radiation doses after pre-incubation with the different
compounds was measured under normoxia and anoxia (Fig. 2D).
As expected, both cell lines demonstrated a more radioresistant
phenotype under anoxic conditions. However, none of the com-
pounds when added before irradiation resulted in enhancement
of the irradiation effect, suggesting the need for a naive tumor
microenvironment.To exclude non-speciﬁc activity of the dual targeting compound
in vivo when investigating the effect of CAIX inhibition on radiation
response, growth delay experiments were repeated for EV and KD
xenografts. All animalswere treatedwithDH348at a similar volume
for both tumor models. DH348 treatment resulted in a signiﬁcant
growth delay (P < 0.01) compared to vehicle controls and sensitized
EV tumors to radiation (P < 0.05) with a SER of 1.45. These effects
were only observed for the CAIX expressing EV tumor model, sup-
porting the speciﬁcity of the CAIX targeted treatment (Fig. 3). Addi-
tionally, no body weight loss was observed for any of the treatment
schedules suggesting no observable systemic toxicity (Fig. S1).
Fig. 3. DH348 (10 mg/kg, 5 days) was administered to EV or KD tumor-bearing animals when tumors reached an average size of 200 mm3 and tumors were irradiated (10 Gy)
at day 3 (set to 0) of this treatment. Tumor growth was monitored until reaching 4 the volume at irradiation time (T4SV). Data represent the mean ± SD of ﬁve to eight
independent animals. Asterisks indicate statistical signiﬁcance (⁄P < 0.05; ⁄⁄P < 0.01).
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CAIX has been associated with cancer progression, metastasis
and poor prognosis through its capacity to regulate intra- and
extracellular acidity of hypoxic tumors [1,4] and is therefore a po-
tential therapeutic target. Recently, CAIX inhibitors have been pro-
posed as potential anti-tumor agents [2,5]. Previously, others and
we have demonstrated that not only CAIX expression, but also hy-
poxia is a requirement to enable accumulation of different classes
of CAIX inhibitors [3,6–8]. Hypoxia causes an acidiﬁcation of the
extracellular environment and studies have demonstrated that
CAIX is the main contributor to this process [3,8,16]. Also in the
current study, genetic silencing of CAIX reduced the hypoxia-in-
duced extracellular acidosis. Additionally, blocking CAIX activity
using sulfamide-based CAIX inhibitors was also able to reduce
extracellular acidiﬁcation up to 40% only upon hypoxia in a
CAIX-dependent manner, in agreement with previously obtained
results using sulfonamide-based inhibitors [6,8].
Hypoxia is a common feature of solid tumors and experimental
and clinical studies have demonstrated that its presence is an
important factor inﬂuencing tumor resistance to radiation therapy
[17,18]. An extensively investigated approach to sensitize tumor to
irradiation, is the use of nitroimidazole-based hypoxic radiosensi-
tizers. The 2-nitroimidazole misonidazole has been shown to be
a very efﬁcient radiosensitizer in experimental and human tumors,however associated with unacceptable systemic toxicity, which
prevented the drug to be given in therapeutically relevant doses
[14]. The less toxic 5-nitroimidazole derivative, nimorazole, has
been shown to reach similar sensitizer enhancement ratios (SER
1.26) in a fractionated radiation schedule (300 mg/kg) as compared
to misonidazole (SER 1.32) but with far less toxicity [14] and is
therefore now used in standard clinical treatment for head and
neck cancer patients in Denmark [15]. Recently, it has been shown
that the tumor response to fractionated irradiation is also depen-
dent on the glycolytic metabolism and therefore on extracellular
acidosis [19]. We have previously shown that CAIX inhibition using
sulfonamide 11c is able to counteract the hypoxic-induced extra-
cellular acidiﬁcation resulting in a sensitization to radiation [8].
Times to reach 4 times the starting volumes (T4SV) were 32.5
(11c) vs 27.8 (vehicle) days for HT-29 parental and 22.2 (11c) vs
17.2 (vehicle) days for EV xenografts [8], resulting in a respective
SER of 1.17 and 1.29.
We therefore designed a dual targeting CAIX-speciﬁc compound
(DH348) composed of a 5-nitroimidazole radiosensitizing hypoxic
cells and a sulfamide targeting active CAIX. We hypothesize that
this compound shows an enhanced sensitization to irradiation in
a CAIX-dependent manner. Reduced CAIX expression was observed
in KD xenografts without affecting the presence of hypoxia as as-
sessed with pimonidazole staining. A recent study reported an en-
hanced pimonidazole labeling upon CAIX silencing. However, this
528 CAIX dual targeting enhances effect IRassociation was only found in spheroids, but not in xenograft mod-
els, emphasizing the requirement of host tissue [20]. Single treat-
ment with DH348 resulted in a slower tumor growth compared
to vehicle treatment only in CAIX expressing tumors. Similar re-
sults were obtained in mammary or colorectal tumor-bearing mice
for which the effect is dependent on the treatment schedule and
the administered dose [8,9,11]. In contrary, a new class of CAIX-
speciﬁc sulfamate inhibitors did not affect primary tumor growth
at low doses, but had signiﬁcant anti-metastatic properties in
breast cancer therapy [12]. Recently, the general CA inhibitor acet-
azolamide has been found to enhance the toxicity of the chemo-
therapeutic agent doxorubicin, with the highest effect for CAIX
expressing cell lines [13]. Therefore, it is promising to pursue spe-
ciﬁc inhibitors of CAIX activity for their capacity to enhance the ef-
fect of conventional therapies.
In the current study, upon treatment with the CAIX-speciﬁc
dual targeting sulfamide DH348, the therapeutic effect of irradia-
tion was enhanced in a CAIX dependent manner (SER 1.50 and
1.45 for HT-29 parental and EV tumors, respectively) without sys-
temic toxicity as evaluated by body weight loss. Higher SER was
found for parental HT-29, which might be explained by higher
CAIX activity, since hypoxic extracellular acidiﬁcation was larger
compared to the EV tumor cells. Furthermore, no sensitization
(SER 1.04) could be observed for the KD tumors. The enhancement
ratios found in the present study are 30% higher compared with the
previously investigated indanesulfonamide [8]. It can be argued
that we did not include the single targeting agents in our animal
study. Previously, we have demonstrated that a single CAIX target-
ing agent showed smaller sensitization effects compared with the
currently investigated dual targeting drug (vide supra) [8]. Addi-
tionally, we observed that the SER of the dual targeting compound
DH348 (10 mg/kg) was also higher than the well-established hyp-
oxic radiosensitizers misonidazole and nimorazole for which a
minimal dose of 100 mg/kg was needed to achieve an SER above
unity [14]. In vitro, no hypoxic radiosensitization was observed
using previously described effective dose regimens [12]. Since also
no radiosensitization was found for the 5-NI single compound
when using equimolar doses, in vitro drug dose levels might be
too low. Nimorazole has been shown to radiosensitize tumor cells,
but this at dose levels 30-fold higher than used in the current study
[21]. We are currently investigating if higher drug doses can radio-
sensitize hypoxic cells in vitro. In the present proof-of-principle
study only one tumor line was investigated and single dose was
applied, which warrants conﬁrmatory investigations using tumor
models of other histology and fractionated radiation schemes.
These experiments as well as mechanistic studies have been initi-
ated in our laboratory. In order to prepare the ﬁrst in human clin-
ical trial, pharmacokinetic, pharmacodynamic and extensive
toxicity studies are currently ongoing.
In conclusion, a newly designed nitroimidazole and sulfamide
based dual targeting drug is able to reduce hypoxic extracellular
acidiﬁcation, to inhibit tumor growth at nontoxic doses and to sen-
sitize tumors to irradiation in a CAIX dependent manner proving
the absence of any ‘‘off-target’’ effect. The dual drug enhances radi-
ation response more effectively as compared to single published
CAIX targeting compounds. Our data therefore indicate the poten-
tial utility of a dual drug approach as a new strategy for tumor-spe-
ciﬁc targeting to eventually improve the response to radiation
treatment.
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